1Seo P, Stone JH. The antineutrophil cytoplasmic antibody associated vasculitides. Am J Med, 2004,117 ( 1 ) :39 - 50.
2de Groot K, J ayne D, Tear V, et al. EUVAS investigators:Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA - associated systemic vasculitis. Kidney Blood Press Res, 2005,28 : 103.
4Hellmich Bernhard, Lamprecht Peter, Gross Wolfgang. Advances in the therapy of wegener' s granulomatosis. Current Opinion in Rheumatology, 2006,18( 1 ) : 25 - 32.
5Thickett DR, Richter AG, Nathani N, et al. Pulmonary manifestations of antineutrophil cytoplasmic antibody (ANCA)positive vasculitis. Rheumatology, 2006,45 (3) : 261 - 268.
7Joy MS, Hogan SL, Jennette JC, et al. A pilot study using mycophenolate mofetil in relap sing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant, 2005,20 (12) : 2725 - 2732.
8Mubashir E, Ahmed MM, Hayat S, et al. Wegener' s granulomatosis: a case report and update. South Med J, 2006, 99 (9): 977 - 988.
9Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission with leflunomide in Wegener' s granutomatosis. Rheumatology,2004,43(3) :315 320.
2Levy JB.New aspects in the management of ANCA positive vasculitis.Nephrol Dial Transplant,2001,16:1314-1317.
3Jayne D,Rasmussen N,Andrassy K,et al.Randomized trial of CTXlophosphamide versus azathioprine as remission maintenance therapy for ANCA-associated vasculitis.N Engl J Med,2003,349:36-44.
4Little MA,Nazar L,Farrington K.Outcome in glomerulonephritis due to systemic small vessel vasculitis:Effect of functional status and non-vasculitic co-morbidity.Nephrol Dial Transplant,2004,19:356-364.
5Hu WX,Liu ZH,Chen HP,et al.Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.Chin Med J,2002,115 (5):705-709.
6Jennette JC,Falk R J,Andrassy K.Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum,1994,37:187-192.
8Exley AR,Bacon PA,Luqmani RA,et al.Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.Arthritis Rheum,1997,40:371-380.
9Joy MS,Hogan SL,Jennette JC,et al.A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis.Nephrol Dial Transplant,2005,20 (12):2725-2732.
10Huang YF,Liu ZH,Huang HD,et al.Effects of mycophenolate acid on endothelial cells.International Immunopharmacplogy,2005,5:1029-1039.
5Mubashir E,Ahmed MM,Hayat S,et al.Wegener's granulomatosis:a case report and update.South Med J,2006,99(9):977-988.
6Nowack R,Gobel U,Klooker P,et al.Mycophenolate mofetil is effective for the maintenance therapy of systemic vasculitis.J Am Soc Nephrol,1997,8:A453.
7田勇泉.耳鼻咽喉科学[M].北京:人民卫生出版社,2008:354.
8Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum,2013,65 ( 1 ) : 1-11.
9Kallcnherg CG. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis,2011,70( 1 ) :59-63.
10Falk R J, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis ( Wegener' s ) : an alternative name for Wegener' s granulomatosis. Arthritis Rheum, 2011,63 ( 4 ) : 863-864.
